| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | -8.99M | -13.95M | -24.22M | -27.65M | -12.48M | -5.95M |
| Depreciation and amortization | 70.0K | 53.0K | 67.0K | 58.0K | 34.0K | 24.0K |
| Stock-based compensation | 623.0K | 617.0K | 1.49M | 3.21M | 2.02M | 130.0K |
| Cash from operations | -11.13M | -15.39M | -23.61M | -20.37M | -12.37M | -5.24M |
| Capital expenditure | -3.0K | 0 | -3.0K | -68.0K | -239.0K | -38.0K |
| Free cash flow | -11.13M | -15.39M | -23.61M | -20.44M | -12.61M | -5.28M |
| Cash from investing | 5.39M | 2.30M | 15.88M | 19.53M | -45.19M | -62.0K |
| Cash from financing | 7.16M | 9.87M | 3.50M | -808.0K | 61.07M | 4.75M |
| Net change in cash | 1.42M | -3.22M | -4.23M | -1.65M | 3.51M | -554.0K |
From Chemomab Therapeutics Ltd.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.